Creative Biotherapeutics, LLC has announced continued progress in the preclinical development of CBT300, an investigational biologic therapeutic candidate. The program is advancing through research, validation, and regulatory preparation focused on mechanisms associated with drug resistance, immune evasion, recurrence, and metastasis. The company is led by clinician Anita Davidson, DPT, and biochemist Dr. Don Davidson, who bring decades of patient care and drug development experience to the effort.
For Anita Davidson, the work is personally motivated by clinical experience, including the recent loss of a sixteen-year-old patient to a rapidly recurring brain cancer. "There are losses that stay with you," Davidson said, noting that such experiences fuel the urgency behind the development. Dr. Don Davidson emphasized that the company's efforts are guided by a focus on biological mechanisms contributing to treatment failure and disease return. "Cancer outcomes are often shaped by recurrence and resistance," he stated, adding that their development work focuses on mechanisms associated with relapse and treatment escape to inform future therapies.
CBT300 is being developed as a multi-mechanism biologic candidate intended to be evaluated for its potential to interfere with drug-resistance pathways, immune-evasion mechanisms, and cellular processes linked to recurrence and metastasis. The company reports that research and validation are ongoing, with development decisions guided by a disciplined, evidence-based approach as it progresses through regulatory preparation. Creative Biotherapeutics is preparing remaining components required to support advancement toward FDA-regulated clinical trials, including continued research, validation, and regulatory readiness. "We are working diligently toward entering clinical trials," Dr. Davidson said. "Progress has to be earned through data, discipline, and integrity."
The company has not announced initial clinical indications for CBT300 but is sharing information publicly to support awareness among patients, clinicians, and the scientific community. It welcomes mission-aligned collaboration inquiries related to the responsible development of CBT300 and the advancement of science-driven oncology solutions, including research collaborations, clinical partnerships, and development opportunities. Collaboration inquiries can be directed via the company's contact portal at https://www.creativebiotherapeutics.com/contact, and more information is available on the official website at https://www.creativebiotherapeutics.com.
Davidson also highlighted tolerability as a key development consideration, noting that patients and families bear the full burden of treatment. "We want development pathways that respect patients and are guided by real-world experience," she said. The company reports issued and pending patents related to its platform and lead program, with the goal of advancing toward FDA-regulated clinical trials through an evidence-based pathway. CBT300 remains investigational and has not been approved by the U.S. Food and Drug Administration, with forward-looking statements subject to risks and uncertainties.
The implications of this development are significant for the oncology field, as addressing drug resistance and recurrence could potentially improve outcomes for patients with aggressive cancers. By targeting multiple mechanisms that contribute to treatment failure, CBT300 represents a novel approach that may offer new options where current therapies fall short. This progress underscores the importance of integrating clinical insights with scientific innovation to tackle persistent challenges in cancer care.
